You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation
|
|---|---|
| Published in |
Frontiers in Pharmacology, January 2012
|
| DOI | 10.3389/fphar.2012.00006 |
| Pubmed ID | |
| Authors |
Gül Erdemli, Albert M. Kim, Haisong Ju, Clayton Springer, Robert C. Penland, Peter K. Hoffmann |
| Abstract |
The human cardiac sodium channel (hNav1.5, encoded by the SCN5A gene) is critical for action potential generation and propagation in the heart. Drug-induced sodium channel inhibition decreases the rate of cardiomyocyte depolarization and consequently conduction velocity and can have serious implications for cardiac safety. Genetic mutations in hNav1.5 have also been linked to a number of cardiac diseases. Therefore, off-target hNav1.5 inhibition may be considered a risk marker for a drug candidate. Given the potential safety implications for patients and the costs of late stage drug development, detection, and mitigation of hNav1.5 liabilities early in drug discovery and development becomes important. In this review, we describe a pre-clinical strategy to identify hNav1.5 liabilities that incorporates in vitro, in vivo, and in silico techniques and the application of this information in the integrated risk assessment at different stages of drug discovery and development. |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 53 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 19 | 35% |
| Student > Ph. D. Student | 7 | 13% |
| Student > Bachelor | 6 | 11% |
| Other | 5 | 9% |
| Student > Doctoral Student | 2 | 4% |
| Other | 6 | 11% |
| Unknown | 10 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 18% |
| Agricultural and Biological Sciences | 9 | 16% |
| Medicine and Dentistry | 8 | 15% |
| Chemistry | 5 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Other | 11 | 20% |
| Unknown | 10 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 March 2018.
All research outputs
#6,379,413
of 22,669,724 outputs
Outputs from Frontiers in Pharmacology
#2,594
of 15,822 outputs
Outputs of similar age
#57,625
of 244,072 outputs
Outputs of similar age from Frontiers in Pharmacology
#33
of 137 outputs
Altmetric has tracked 22,669,724 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 15,822 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,072 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 137 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.